SOURCE: Kessler Topaz Meltzer & Check, LLP

June 11, 2015 09:30 ET

AERIE PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Important Deadline -- AERI

RADNOR, PA--(Marketwired - Jun 11, 2015) - The law firm of Kessler Topaz Meltzer & Check, LLP announces that a shareholder class action has been filed against Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) ("Aerie" or the "Company") on behalf of purchasers of the Company's common stock between August 6, 2014 and April 23, 2015, inclusive (the "Class Period"), and reminds Aerie shareholders that they may, no later than June 29, 2015, petition the Court to be appointed as a lead plaintiff of the class.

For additional information about this lawsuit, or to request information about this action online, please visit http://www.ktmc.com/case/AeriePharmaceuticals.

Aerie shareholders who wish to discuss this action and their legal options are encouraged to contact Kessler Topaz Meltzer & Check, LLP (Darren J. Check, Esq., D. Seamus Kaskela, Esq. or Adrienne O. Bell, Esq.) at (888) 299-7706 or at info@ktmc.com.

The class action complaint alleges that, throughout the Class Period, Aerie and certain of its executive officers made a series of false and misleading statements and/or failed to disclose material adverse information about the future prospects for Rhopressa.

On April 23, 2015, Aerie issued a press release announcing the results of its first Phase 3 registration trial for Rhopressa. According to the press release, "[t]he trial did not meet its primary efficacy endpoint of demonstrating non-inferiority of IOP lowering for once-daily Rhopressa compared to twice-daily timolol, the most widely used comparator in registration trials for glaucoma." On this news, shares of Aerie's stock fell $22.52 per share, or over 63 percent, to close on April 24, 2015 at $12.87 per share.

If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check (Darren J. Check, Esq., D. Seamus Kaskela, Esq. or Adrienne O. Bell, Esq.) at (888) 299 - 7706 or (610) 667 - 7706, or via e-mail at info@ktmc.com. For additional information about the lawsuit, or to request information about the action, please visit http://www.ktmc.com/case/AeriePharmaceuticals.

Aerie shareholders may, no later than June 29, 2015, petition the Court to be appointed as a lead plaintiff of the class. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class in the action. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Any member of the purported class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. The complaint in this action was not filed by Kessler Topaz Meltzer & Check. 

Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). For more information about Kessler Topaz Meltzer & Check, or for additional information about participating in this action, please visit www.ktmc.com.

Contact Information

  • CONTACT:
    Kessler Topaz Meltzer & Check, LLP
    Darren J. Check, Esq.
    D. Seamus Kaskela, Esq.
    Adrienne O. Bell, Esq.
    280 King of Prussia Road
    Radnor, PA 19087
    (888) 299 - 7706
    (610) 667 - 7706
    Email Contact